• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Monoclonal antibody treatment does not improve outcomes in COVID-19-positive pregnant patients

byGrace YinandKiera Liblik
November 30, 2022
in Infectious Disease, Obstetrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Monoclonal antibody (mAb) treatment for mild to moderate coronavirus disease 2019 (COVID-19) in pregnant persons was not associated with a change in COVID-19-associated outcomes compared to usual care.

2. Treatment with mAb was also not associated with serious adverse reactions in this population. 

Evidence Rating Level: 2 (Good)

Study Rundown: In some studies, mAb infusions, such as bamlanivimab and etesevimab, have reduced morbidity and mortality among patients infected with COVID-19. Although pregnancy has been found to be a risk factor for severe COVID-19 outcomes, the safety and efficacy of mAb treatments for pregnant persons infected with COVID-19 are unclear. This study was a retrospective cohort study of pregnant persons aged 12 and older who presented to an eligible outpatient care center with a positive COVID-19 test. It aimed to characterize the incidence of drug-related adverse events and to evaluate whether treatment with mAb was associated with a change in hospitalization or deaths. The study found that adverse reactions with mAb were rare and that mAb treatment was not associated with a change in COVID-19 outcomes, hospitalization, or obstetrical outcomes. However, further investigation into the study objectives may be required, as the retrospective nature of this study lends to significant recall bias and residual confounding. Symptom severity of COVID-19 was only documented for those receiving mAb, and adverse events may have been underreported. There were also several significant imbalances in baseline characteristics between the group which received mAb and the group which did not.

Click to read the study in AIM

In-Depth [retrospective cohort]: This retrospective study evaluated the safety and effectiveness of mAb treatments among pregnant persons with a documented COVID-19 infection between April 30, 2021 and January 21, 2022. Pregnant persons aged 12 and older who presented to a UPMC Health System care center as an outpatient within seven days of symptom onset were included. After applying selection criteria, 944 participants were included, of which 552 were found to have received mAb treatment. Results of the primary analysis found mild drug-related adverse events occurred in eight patients who were treated (1.4%) without the occurrence of a severe reaction. There was no difference in obstetric-associated outcomes between those who received mAb and those who did not. In terms of effectiveness, the propensity score-matched risk ratio for 28-days COVID-19 associated outcomes was 0.61 (95% Confidence Interval [CI], 0.34 to 1.1), and no difference in the propensity score-matched rates of non-COVID-19 related hospital admissions (risk ratio, 1.3; 95% CI 0.58% to 2.8%). At baseline, there were also significant differences between participants within the mAb treatment and non-treatment groups, namely that mAb patients were older, more likely to have private insurance, more likely to have a lower median area of deprivation index score, and more likely to be fully vaccinated against COVID-19. Overall, this study provided evidence that adverse events related to mAb treatment within this population were mild and rare. From an effectiveness standpoint, mAb did not show superior outcomes compared to mAb non-treatment.

Image: PD

RELATED REPORTS

Guidelines from many countries recommend physical activity during uncomplicated pregnancy

Wellness Check: Exercise

Nirmatrelvir-ritonavir combination reduces hospitalization and mortality in COVID-19

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Coronavirus disease 2019COVID-19infectious diseasemonoclonal antibodiesobstetricspregnancypublic health
Previous Post

Low-dose ketamine may reduce shivering following spinal anesthesia

Next Post

Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation

RelatedReports

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity
Obstetrics

Guidelines from many countries recommend physical activity during uncomplicated pregnancy

February 3, 2023
Few older adolescents meet recommended levels of physical activity
Wellness

Wellness Check: Exercise

February 2, 2023
Ultrasound enhances gastrointestinal absorption of drugs at low frequencies
Emergency

Nirmatrelvir-ritonavir combination reduces hospitalization and mortality in COVID-19

February 1, 2023
Mental health parity law associated with financial protection for children
Endocrinology

Gender-affirming hormones improve psychosocial functioning in transgender youth

January 31, 2023
Next Post
Cardiac mortality paradoxically lower during times of national cardiology conferences

Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival

#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options